Standards for opioid use disorder care : An assessment of Nordic approaches by Gedeon, Charlotte et al.
Overview
Standards for opioid
use disorder care:
An assessment of
Nordic approaches
Charlotte Gedeon
Solstenen Addiction Centre, Ska˚ne, Sweden
Mikael Sandell
Capio Maria, Stockholm and Ska˚ne, Sweden
Inge Birkemose
Odense Kommune, Misbrugsbehandling, Denmark
Johan Kakko
Umea˚ University, Sweden
Valgerður Ru´narsdo´ttir
SAA’s Vogur Hospital, Reykjavik, Iceland
Kaarlo Simojoki
Helsinki University Hospital, Finland A-Clinic Foundation/
A-clinic oy, University of Helsinki, Finland
Thomas Clausen
Norwegian Centre for Addiction Research, University of
Oslo, Norway
Fred Nyberg
Uppsala University, Sweden
Richard Littlewood
applied strategic, London, UK
Hannu Alho
Abdominal Centre, University of Helsinki and Helsinki
University Hospital, Helsinki, Finland
Abstract
Aims: Outcomes in opioid use disorder (OUD) in Nordic countries have improved with inte-
grated treatment and harm-reduction programmes. Approaches and the standard of care are
different across the region. Evidence of treatment needs and current approaches are defined from
evidence to inform development of a common standard. Method: Evidence of population sizes
and treatment approach collected. Common standards for care (harm reduction, pharma-
cotherapy, psychology/social therapy) defined for each country. Results: Evidence defines number
in treatment; potential population needing treatment not defined for all countries. Populations
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sizes, treatment access (ratio in treatment programme compared to total country population)
defined: Sweden 4,000 in OUD care (access ratio 40); Finland 3,000 (55); Norway 8,000 (154);
Denmark 7,500 (132). Approach to treatment similar: integrated treatment programmes standard.
Care provided by specialists in outpatient clinics/primary care; secondary care/inpatient services
are available. Harm reduction is limited in Sweden but available and more accessible elsewhere.
Treatment entry criteria: access relatively unlimited in Norway and Denmark, more limited in
Finland and Sweden. Standards of care defined: easy access to high-quality services, individual
planning, care not limited by time, management of relapse, education for patients, continuous
engagement, holistic approach including management of comorbidities, needle equipment pro-
grammes without limit, treatment in prisons as community.Conclusion: There are opportunities
to improve OUD care in the Nordics. Policy makers and clinicians can advance OUD care and
share common success factors. Collaborative work across the Nordic countries is valuable.
Further research in clinical practice development can yield important results for the benefit of
patients with OUD.
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Opioid use disorder (OUD) is associated with
risk of mortality and morbidity (Dematteis
et al., 2017) including adverse mental and
somatic health outcomes, poor perceived qual-
ity of life, unemployment (Callahan et al.,
2015), homelessness (National Alliance to End
Homelessness, 2016), family disruption, social
instability, criminal activities (Daley, 2013) as
well as loss of economic productivity (Jiang,
Lee, Lee, & Pickard, 2017). Pharmacotherapy
with opioid agonist therapy (OAT) in an inte-
grated programme with psychosocial care is
proven to improve outcomes and can address
the health and social consequences of OUD
(Nielsen et al., 2016). Needle equipment pro-
grammes are effective in limiting harms from
blood-borne viruses. Other approaches such as
mutual help and Narcotics Anonymous are also
important treatment options.
Sweden, Denmark, Finland, Norway, and Ice-
land have similar welfare and national healthcare
systemapproacheswith open access to healthcare
in general. There are similarities in substance-use
culture across these countries (Selin et al., 2015)
and guidance for treatment of peoplewithOUDis
available in Sweden (Socialstyrelsen, 2015),
Denmark (Sundhedsstyrelsen, 2017), Finland
(Alho et al., 2012), Norway (Helsedirektoratet,
2016), and Iceland (SAA National Center of
Addiction Medicine, 2016).
Pharmacotherapy is an established part of
treatment systems in these countries (Skretting
& Rosenqvist, 2010); although approaches to
OUD care differ in each country. This work
compares population needs and approaches to
OUD care across the region to define standards
for practice.
Materials and methods
A comparison of approaches to OUD care was
completed; care was described by collecting
evidence of relevant populations, service type
and access. Evidence describing the size,
access, and approach for OUD care was col-
lected from publications of national agencies
concerned with substance-use disorders and
peer-reviewed publications recommended by
experts in the therapy area. Evidence sources
were selected in a standard manner retrieving
the most recent official government data
describing OUD populations. Two reviewers
familiar with the field assessed the evidence
sources independently and extracted relevant
Gedeon et al. 287
data. Results of the evidence collection and
analysis were reviewed by experts in the field
(more than 10 years’ experience in OUD care in
the relevant countries). A recommendation for a
standard of care was developed based on a com-
parison of current observed approaches across
countries.
Results
Assessment was completed for Sweden, Den-
mark, Finland, Norway, and Iceland (Table 1).
Population treatment needs and access
In Sweden, the population with potential need
for OUD care is likely 29,500, as based on
national patient and prison registries (Statens
Folkha¨lsoinstitut, 2010); other sources describe
different groups within this population includ-
ing point prevalence estimates of persons
involved in injecting drugs and those involved
in heroin use (8,000–13,000) (Folkhalsomyn-
digheten, 2014; Urban, Lindholm, & Sa¨fven-
berg, 2016). In Denmark, the population with
potential need for OUD care is 13,000 based on
the national health registry data (Selin et al.,
2015; Skretting & Rosenqvist, 2010; Sundheds-
styrelsen, 2014). In Finland, the number of
problem opioid users is estimated to be
15,000 based on national hospital discharge
registries and the police information system
(Ollgren et al., 2014; Selin et al., 2015; Varjo-
nen, 2014). In Norway, the population of high-
risk opioid users or number of injecting drug
users is 7,700–12,600 (SIRUS Norwegian
Institute for Alcohol and Drug Research,
2014; Skretting & Rosenqvist, 2010) based on
mortality data on drug-related deaths and
questionnaire-based surveys among policy and
social services. In Iceland, the population of
active opioid users is 200 from the main sub-
stance misuse treatment centre (unpublished
data, 2017). Opioid use profiles among people
with OUD differ: injected heroin use is com-
mon in Denmark (Skretting & Rosenqvist,
2010), Norway (Helsedirektoratet, 2010;
Bretteville-Jensen & Amundsen, 2006), and
Sweden (Skretting & Rosenqvist, 2010); illicit
use of diverted buprenorphine is predominant in
Finland (Selin et al., 2015); in Iceland almost
all patients attending OUD treatment reported
predominantly injected morphine use (Ru´nars-
do´ttir, 2014). Relative levels of treatment
engagement for the countries assessed are dif-
ferent. Estimated numbers engaged with treat-
ment programmes are Norway (8,000)
(Granerud & Toft, 2015), Denmark (7,500)
(Sundhedsstyrelsen, 2014), Sweden (4,000)
(Most recent estimate, likely an underestimated
figure) (Socialstyrelsen, 2017), Finland (3,000)
(National Institute for Health and Welfare Fin-
land, 2017) and Iceland (130) (unpublished
data, 2017). The index of treatment access
(based on the number of patients in OUD care,
annual estimate, as a ratio of the total national
population, all citizens) indicates higher access
to OUD care in Norway (ratio 154) and Den-
mark (132); access to care is more limited in
Finland (55) and Sweden (40). (Iceland was not
assessed due to small national population.)
Approach to treatment
The approach to OUD management is defined
for each country (Table 2). The approach to
OUD care is similar across the Nordic countries;
treatment is based on integrated programmes of
OATmedication and psychosocial therapy in the
context of similar welfare and national state-
provided healthcare systems. Housing and social
benefits, such as long-term disability pension,
may be provided when appropriate from the
municipality.
Outpatient care based on similar integrated
programmes of medical and psychosocial ther-
apy is the common model for treatment of OUD
in all countries (Skretting & Rosenqvist, 2010).
In Sweden and Iceland, patients may be advised
or required to start with inpatient care under
intensive monitoring (Hansdo´ttir, Ru´narsdo´ttir,
& Tyrfingsson, 2013). Criteria to enter treat-
ment programmes described in national guide-
lines differ across countries. In Denmark,
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Finland, Iceland and Norway criteria for access
to services are minimal. In Sweden, a diagnosis
of OUD for at least 12 months is required for
treatment entry and the minimum age for
receiving OAT is 20 years old with exceptions
for special reasons (Socialstyrelsens, 2016).
Choice of medication options for OUD man-
agement varies. Common choices for OAT
include methadone, buprenorphine/naloxone
fixed-dose combination product, and single
agent monotherapy with buprenorphine.
Methadone is the most common choice in Den-
mark (Selin, 2013; Selin et al., 2015); bupre-
norphine and fixed-dose combination product
of buprenorphine/naloxone are widely used in
Sweden (Selin et al., 2015; Socialstyrelsen,
2012) and Norway (Ding, Mosdøl, Hov, &
Staumann, 2016; Selin et al., 2015). In Finland,
buprenorphine/naloxone is most common: there
is very limited prescribing of buprenorphine as
a result of the common practice of buprenor-
phine misuse and diversion (Selin et al., 2015;
Varjonen, 2014). In Iceland most patients are
treated with buprenorphine/naloxone (Hansdo´t-
tir et al., 2013; Selin et al., 2015).
All countries operate some form of inte-
grated needle equipment programme (NEP)
for harm reduction; accessibility is high in
Denmark (Bjerge, Duke, & Frank, 2015),
Finland (National Institute of Health and
Social Welfare, 2016), Iceland (Fridjonsdottir,
2016), and Norway (Norwegian Institute for
Alcohol and Drug Research, 2012). In Swe-
den, access to NEP was restricted until 2017;
progress has been made but access is still dif-
ficult or limited for many people (Folkha¨lso-
myndigheten, 2017; Swedish National
Institute of Public Health, 2012).
Discussion
Effective OUD treatment improves outcomes:
it reduces illicit drug use and demand on the
illicit drug market at individual and community
levels (Dematteis et al., 2017; Sumnall, Bates,
& Jones, 2017; Wodak, 2011), potentially lim-
iting future opioid use (The National Center on
Addiction and Substance Abuse, 2017). Access
to long-term and sustained coverage of harm
reduction interventions is associated with lower
levels of risky behaviour and lower prevalence
of infectious diseases (Martin et al., 2012;
Strang et al., 2012; Vickerman, Martin, Turner,
& Hickman, 2012).
In theory, OUD treatment is available for all
citizens at no or insignificant cost in the coun-
tries assessed, all of which have similar health-
care systems. Despite this similar foundation,
this work shows important differences in OUD
care for Nordic countries. Access to care is dif-
ferent with higher levels of engagement in
Norway and Denmark, and lower levels in Swe-
den and Finland. Entry criteria are an important
determinant of this difference. Access to ser-
vices to reduce harm, such as needle equipment
programmes, is limited in Sweden and reduces
the ability of citizens to avoid preventable risk
behaviour. This access level has changed in
Sweden but remains distinctly different from
other countries.
This summary of the differences and simila-
rities in OUD care across this region is the basis
for a definition of a set of simple standards
which should apply generally. These are
described in groups considering a journey a
patient might take from initial engagement to
assessment and treatment:
During “Engagement, diagnosis and treatment
assessment”, making decisions openly and
in collaboration with patients, including
confirmation of theOUDdiagnosis, record-
ing all drug use, assessing somatic and psy-
chiatric co-morbidities, and discussing
treatment options are important.
Developing a treatment or management plan
centred around relevant goals, tailored to
individual needs, is important. This
includes assessment of different starting
points, risks, treatment goals, potential
outcomes, with patients being well-
informed on the scope of long-term care
and the standards for the expected level of
conduct and compliance.
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For treatment choice, ongoing therapy and
completion, it is important to adopt an inte-
grated approach considering elements of
pharmacotherapy, psychiatric and social
interventions, which is holistic and
includes the management of other frequent
somatic co-morbidities such as hepatitis C
virus (HCV), HIV, and other mental health
problems for successful outcomes.
Important outcomes include control of crav-
ing, ongoing opioid and other drugs con-
sumption, and management of somatic
and psychiatric comorbidities, as well
as subjective improvement of overall
quality of life.
Buprenorphine/naloxone, buprenorphine and
methadone are common choices in phar-
macotherapy: decision making should be
based on a careful consideration of effi-
cacy, safety, comorbidities, any preceding
treatments, guidelines and patients’ pre-
ference and individual needs (Dematteis
et al., 2017). Buprenorphine/naloxone
fixed-dose combination product is recom-
mended in national treatment guidelines
as a key choice (Alho et al., 2012; Helse-
direktoratet, 2010; Socialstyrelsen, 2017;
Sundhedsstyrelsen, 2008). The choice of
medical product should not preclude focus
on planning other forms of social support
such as stable housing, employment, and
other meaningful daily activities that are
important in promoting wider improve-
ment in all aspects of life.
At the beginning of the treatment pro-
gramme, more intensive input is recom-
mended to allow close monitoring and
careful titration to ensure patients receive
an appropriate OAT dose, and to minimise
risks of overdose and likelihood of prob-
lems with “on top” opioid use.
As treatment progresses and patients stabi-
lise, regimens may evolve from intensive
daily visits towards self-management of
picking up doses from a pharmacy. An
assessment for suitability of take-home
medication should be implemented
across all treatment services. For patients
using take-home medication, it is impor-
tant to ensure continuous contact with
clinical professionals to help predict
problems, avoid risk and relapse, mini-
mise risk of diversion, and provide assis-
tance if necessary.
A flexible treatment plan with scope for
changes, based on patients’ preferences
and ongoing assessment, improves out-
comes; an inflexible plan may be counter-
productive. Treatment duration should not
be limited based on arbitrary grounds –
treatment can continue for as long as
needed, with continuous support from an
integrated team of stakeholders according
to patients’ perceived needs for counsel-
ling and assistance. Developing a working
approach with patients’ input, with regu-
lar reviews of goals and progress, offers
the opportunity to educate patients to con-
duct self-evaluation to catch early signs of
relapse and actively ask for help.
Relapse is common and should be consid-
ered as part of the recovery process.
Relapse can be addressed with increased
intensity of planned intervention, for
example more regular visits to clinics,
more input from psychosocial support
such as counselling and peer support. The
choice of medication and dosage should
be reconsidered; dose might need to be
increased if there are signs of “on top”
opioid use. Concomitant health problems
such as psychiatric co-morbidities may
need to be reassessed and treated.
Some patients may complete therapy with
significant support by a carefully pro-
grammed approach; careful planning of
timing and assessment of patients’ moti-
vation and decisions are important.
Achieving abstinence should be planned
carefully and agreed with the patient, with
a thorough discussion on whether he or
she is sufficiently motivated and has the
personal and social stability to cope and
solve problems.
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A pragmatic approach for both the delivery
of evidence-based treatment, i.e., OAT
and harm reduction, is important. Wide
access to harm reduction will potentially
serve as an entry point to services for
those underserved for healthcare and hard
to reach, and it may be a first step towards
more formal care. On a practical level,
access to NEP and other harm-reduction
interventions should be offered without
restriction. Increase in differentiated treat-
ment options tailored to individualised
needs should be considered in countries
with lower participation in therapy.
Examples such as primary care and NEP
centres as key points of treatment entry
and evaluation can be considered. Treat-
ment should be widely available including
in prisons. Prison OUD care should be the
same high quality as community care.
Treatment for comorbidities including
mental health and HCV infection should
be easily available.
This work defines the needs of populations
based on available evidence describing OUD
groups. It is difficult to estimate the size of
populations with OUD because of the criminal
nature of illicit drug use. Evidence collected
here represents the best available profile of
populations with OUD; population estimates
and related needs for treatment can be improved
with further work. An index of persons
recorded in treatment compared to national
country population is used. This is not ideal,
and it would be more conventional to compare
to total population potentially requiring treat-
ment. The total value is not available for Swe-
den and introducing this figure as an estimate is
problematic and likely would remove the focus
from the insights to be drawn from the metric
used. Research – including collaborative
regional programmes with common approaches
to measurement – to identify the size and types
of the population needs and reasons for non-
participation should be supported. Evidence on
the impact of the continuing observed levels of
access to treatment in OUD can be used to sup-
port future policy decisions that promote con-
tinuing access to integrated treatment with
OAT. This can include comparative analysis
leveraging existing similar population attributes
and approaches to healthcare in general with the
opportunity presented by existing pan-Nordic
healthcare registries of activity and outcomes
healthcare data. Insights from this research are
key to making decisions about the future of OUD
care aiming to achieve increased engagement to
address dependence, improve overall health with
management of comorbidities, quality of life and
citizen participation leading to better social and
family outcomes matched with reduced criminal
activity and wider benefits to society.
Conclusion
Progress in OUD care and improvement in out-
comes has been significant since the introduc-
tion of integrated treatment and harm-reduction
programmes. National policy and practice must
be optimal to ensure equity of access to services
providing easy access to high-quality treatment
programmes with OAT and NEP. Decision
makers including policy makers, providers of
services, researchers and clinicians can improve
outcomes by adopting and extending observed
best practice across the region.
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